Application of PPARD gene in preparation of medicine for regulating and controlling toxicity of mycotoxin

Through the overexpression of PPARD gene and curcumin activation, oxidative stress and tight connection between cells are regulated, the prevention and control problems of mycotoxin toxicity are solved, effective detoxification of OTA and intestinal barrier protection are achieved, and a safe and Effective biological control methods.

CN118949074AActive Publication Date: 2024-11-15YANGZHOU UNIV
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202411026164.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-30
Publication Date
2024-11-15
Estimated Expiration
2044-07-30

AI Technical Summary

Technical Problem

The problem of the existing technology is difficult to effectively prevent and control the toxicity of mycotoxins, especially ochratoxin A (OTA), and the existing detoxification methods are costly and inefficient, which affect the nutritional value of the feed.

Method used

Detoxify mycotoxins by utilizing the PPARD gene or its encoding protein, especially by overexpressing or activating the PPARD gene, using curcumin as a PPARD activator, regulating oxidative stress and tight cell junctions.

Benefits of technology

It has achieved effective detoxification of mycotoxins, reduced their toxic effects, protected intestinal barriers, reduced oxidative stress and tight connection damage, and provided a safe and effective biological control method to prevent and control mycotoxin poisoning.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004968594930000021
    Figure BDA0004968594930000021
  • Figure BDA0004968594930000051
    Figure BDA0004968594930000051
  • Figure BDA0004968594930000052
    Figure BDA0004968594930000052
Patent Text Reader

Abstract

The invention discloses an application of a PPARD gene in preparation of a medicine for regulating and controlling toxicity of mycotoxin. According to the invention, the PPARD gene or the encoded protein thereof can be used as a target for relieving the toxicity of mycotoxin for the first time; the invention firstly proposes that the toxic effect of mycotoxin can be reduced by activating PPARD gene expression, and oxidative stress and tight junction disruption induced by the mycotoxin can be relieved by overexpressing the PPARD gene at a cellular level; according to the application disclosed by the invention, the Curcumin plays a role in relieving the toxicity of the mycotoxin by activating the expression of the PPARD for the first time.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to application of PPARD gene in preparing medicine for regulating the toxicity of mycotoxins, and belongs to the field of biological control of mycotoxins. Background Art

[0002] Mycotoxins are toxic secondary metabolites produced by molds. They are widely present in mold-contaminated grains and feeds, posing a great threat to human and animal health. With the increasing public attention to feed safety and the resulting safety of livestock and poultry products, mycotoxin contamination has become an important issue that needs to be urgently addressed in the livestock and poultry breeding process. Among the currently known mycotoxin families, ochratoxin A (OTA) ranks second, second only to aflatoxin, in terms of toxicity and harmfulness. OTA has strong nephrotoxicity, hepatotoxicity and enterotoxicity. The intake and accumulation of OTA can cause organ damage. Existing studies have mainly focused on OTA nephrotoxicity and hepatotoxicity, while there are fewer studies on its enterotoxicity. The intestine is the main site for the digestion and absorption of nutrients, and it is also the largest endocrine and immune organ in the body. As a selective barrier, the intestinal barrier can effectively prevent exogenous harmful substances such as pathogenic microorganisms and toxins from entering the circulatory system. The integrity of the intestinal barrier plays an important role in maintaining the health of the body.

[0003] Although there are various mycotoxin detoxification methods, they are difficult to completely eliminate the risk of livestock and poultry being exposed to OTA due to many limitations such as high cost, low efficiency and impact on the nutritional value of feed. Finding a safe and effective method to prevent and control the toxic effects of OTA is an urgent need for mycotoxin prevention and control, and biological methods are considered to be a promising prevention and control strategy.

[0004] Peroxisome proliferator-activated receptor-δ / β (PPARD) is an important member of the nuclear receptor PPAR family, which has regulatory effects on fatty acid metabolism, obesity, wound healing, apoptosis and inflammation. PPARD has been used as a target in the clinic to treat metabolic disorders such as dyslipidemia. At the same time, PPARD can also protect epithelial cells from oxidative stress-induced apoptosis and inflammation by upregulating antioxidant enzymes. However, no studies have reported the regulatory effect of PPARD on mycotoxin toxicity and its related mechanisms. Summary of the invention

[0005] Purpose of the invention: The technical problem to be solved by the present invention is to provide for the first time the use of the PPARD gene in the preparation of drugs for regulating the toxicity of mycotoxins, which can serve as a target for alleviating the toxicity of mycotoxins.

[0006] Technical solution: To solve the above technical problems, the present invention provides the use of the PPARD gene or its siRNA in the preparation of a drug for regulating the toxicity of mycotoxins, and the accession number of the PPARD gene is NM_001130241.3.

[0007] The present invention also provides the use of the PPARD gene or the protein encoded by it in preparing a drug for preventing and / or treating mycotoxin poisoning.

[0008] The present invention also provides the use of the PPARD gene or the protein encoded by it in preparing a drug for alleviating the toxicity of mycotoxins.

[0009] Among them, PPARD plays a role in mycotoxin detoxification by regulating oxidative stress and tight junctions between cells.

[0010] Among them, it includes overexpressing the PPARD gene or activating the expression of the PPARD gene.

[0011] Wherein, the method for activating PPARD gene expression comprises using a PPARD activator.

[0012] Wherein, the PPARD activator comprises Curcumin, and the chemical formula of Curcumin is as follows:

[0013]

[0014] Furthermore, the activator exerts a detoxifying effect on mycotoxins by increasing the expression of PPARD mRNA and protein.

[0015] The dosage forms of the drug include oral solution, injection, tablet, pill, dispersant, capsule, pellet, granule, suspension or emulsion.

[0016] The present invention also provides the use of curcumin in preparing a medicine for preventing and / or treating mycotoxin poisoning.

[0017] Wherein, the curcumin activates PPARD gene expression.

[0018] The dosage forms of the drug include oral solution, injection, tablet, pill, dispersant, capsule, pellet, granule, suspension or emulsion.

[0019] The present invention also provides the use of peroxisome proliferator-activated receptor-δ / β as a target for mycotoxin detoxification. At the same time, in order to overcome the deficiencies in the prior art, a natural compound targeting PPARD to prevent and treat mycotoxin poisoning is provided, in order to provide a new approach for biological control of mycotoxin poisoning.

[0020] The present invention also provides a drug capable of preventing and / or treating mycotoxin toxicity, wherein the drug can activate the expression of PPARD gene or protein.

[0021] The drug detoxifies mycotoxins by increasing cell activity, inhibiting oxidative stress and enhancing tight junctions between cells.

[0022] Wherein, the medicine also includes curcumin.

[0023] The present invention also provides a method for studying the function of genes related to mycotoxin detoxification, or screening drugs for preventing or treating mycotoxin enterotoxicity, or constructing a mycotoxin exposure model, or analyzing drugs that target genes to alleviate mycotoxin toxicity, the method comprising overexpressing the PPARD gene, reducing the expression of the PPARD gene, or activating the expression of the PPARD gene.

[0024] Preferably, the method of overexpressing the PPARD gene includes constructing a PPARD overexpression vector using a pECMV-MCS-FLAG plasmid, and the primer nucleotide sequences are shown in Table 1.

[0025] Wherein, the method of reducing the expression of PPARD gene includes using siRNA, and the siRNA includes si-PPARD-1, si-PPARD-2 and si-PPARD-3. The nucleotide sequence of the siRNA is shown in Table 2.

[0026] Beneficial effects: Compared with the prior art, the present invention has the following significant advantages: 1. The present invention proposes for the first time that the PPARD gene or its encoded protein can be used as a target for alleviating the toxicity of mycotoxins; 2. The present invention proposes for the first time that activating the expression of the PPARD gene can alleviate the toxic effects of mycotoxins, and overexpressing the PPARD gene at the cellular level can alleviate the oxidative stress and tight junction damage induced by mycotoxins; 3. The present invention proposes for the first time that Curcumin can alleviate the toxicity of mycotoxins by activating the expression of PPARD. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] Figure 1 Figure 1 shows the regulatory effect of PPARD overexpression on OTA cytotoxicity, where Figure A shows the changes in mRNA expression levels in PPARD overexpressing cells; Figure B shows the expression levels of tight junction proteins ZO-1, Occludin and Cludin-1 in PPARD overexpressing cells treated with OTA; Figure C shows the oxidative stress levels in PPARD overexpressing cells treated with OTA; *** P < 0.001;

[0028] Figure 2Figure 1 shows the activation effect of curcumin on PPARD expression. Figure A shows the expression level of PPARD mRNA in cells treated with curcumin at different concentrations; Figure B shows the expression level of PPARD protein in cells treated with curcumin at different concentrations. CUR: curcumin, ** P < 0.01;

[0029] Figure 3 Figure 1 shows the regulatory effect of curcumin on OTA-induced cytotoxicity. Figure A shows the oxidative stress level in different addition groups of OTA and curcumin; Figure B shows the ROS level in cells of different treatment groups; Figure C shows the expression levels of tight junction proteins ZO-1, Occludin and Cludin-1 in different addition groups of OTA and curcumin; CUR: curcumin, ** P < 0.01;

[0030] Figure 4 Figure 1 shows the effect of PPARD interference on curcumin's alleviation of OTA cytotoxicity. Figure A shows the changes in PPARD mRNA expression levels in cells transfected with different siRNA fragments; Figure B shows the expression levels of tight junction proteins ZO-1, Occludin, and Cludin-1 in cells with PPARD expression interference after adding OTA and curcumin; CUR: curcumin, ** P<0.01, *** P<0.001. DETAILED DESCRIPTION

[0031] The technical solution of the present invention is further described below in conjunction with the accompanying drawings.

[0032] The main materials and reagents used in the examples are as follows:

[0033] (1) Experimental materials: IPEC-J2 cells (kept in our laboratory); pECMV-MCS-FLAG (Wuhan Miaoling Biotechnology Co., Ltd., P0787).

[0034] (2) Experimental reagents: ochratoxin A (OTA, Qingdao Prebon Biotechnology Co., Ltd.); curcumin (MedChemExpress Biotechnology Co., Ltd., USA); DMEM high glucose medium (HyClone, USA); fetal bovine serum, Opti-MEM medium (Thermo Fisher Scientific, USA); penicillin-streptomycin mixture, reactive oxygen species detection kit, RIPA lysis buffer (Beijing Solebow Technology Co., Ltd.); Cell Counting Kit-8 kit (Japan DOJINDO Technology Co., Ltd.); protease inhibitors, BCA protein content detection kit (Shanghai Biotech Co., Ltd.); 5× SDS-PAGE protein loading buffer, color prestained protein marker (Shanghai Yisheng Biotech Co., Ltd.); PVDF membrane (Millipore, USA); PAGE gel rapid preparation kit (Shanghai Yazyme Biopharmaceutical Technology Co., Ltd.); PPARD (AF7800) (Shanghai Biotech Co., Ltd.); ZO-1 (ab221547) and Claudin-1 antibodies (ab15098) (Abcam (Shanghai) Trading Co., Ltd.); Occludin (27260-1-AP) and GAPDH antibodies (10494-1-AP) (Wuhan Sanying Biotechnology Co., Ltd.); horseradish peroxidase-conjugated goat anti-mouse (HA1006) secondary antibody and goat anti-rabbit (HA1001) secondary antibody (Hangzhou Huaan Biotech Co., Ltd.); ultrasensitive ECL chemiluminescence kit (Suzhou Xinsaimei Biotech Co., Ltd.); TRIzol RNA extraction reagent (Bao Bioengineering (Dalian) Co., Ltd.); cDNA synthesis kit, fluorescence quantitative detection kit, high-fidelity DNA polymerase (P501), DNA purification and recovery kit, homologous recombination kit (Nanjing Novogene Biotechnology Co., Ltd.); DH5α competent cells (Beijing Qingke Biotechnology Co., Ltd.); endotoxin-free plasmid mini- and midi-precipitation kit (Beijing Tiangen Biochemical Technology Co., Ltd.); jetPRIME universal in vitro transfection reagent (Polyplus Biotechnology Co., Ltd., France).

[0035] The specific steps of the experimental method used in the embodiment are as follows:

[0036] 1. Construction of PPARD overexpression and interference vector

[0037] (1) Construction of PPARD overexpression vector

[0038] a. The gene sequence of PPARD was searched in the NCBI database (Gene ID: NM_001130241.3), pECMV-MCS-FLAG was used as a vector, primers were designed by homologous recombination, and the CDS region of PPARD was amplified using a high-fidelity DNA polymerase (the specific sequence after amplification is shown in SEQ ID NO: 1), the amplification system is shown in Table 1, and the reaction procedure is shown in Table 2. The primers used were synthesized by Nanjing Qingke Biotechnology Co., Ltd., and the specific primer sequences are shown in Table 3.

[0039] Table 1 PPARD amplification system

[0040]

[0041] Table 2 PPARD amplification reaction procedure

[0042]

[0043] Table 3 Overexpression vector primer sequences

[0044]

[0045] b. After the above amplified product was purified and recovered, the PPARD gene amplified sequence was connected to the linearized vector by homologous recombination according to the instructions. The connection system (20 μL) was: pECMV-MCS-FLAG linearized vector 0.03 pmol, insert fragment 0.06 pmol, 5×CE II Buffer 4 μL, Exnase II 2 μL, ddH 2 O to 20 μL. After gently blowing and mixing, the reaction solution was collected at the bottom of the tube. After reacting in a 37°C metal bath for 30 minutes, it was immediately placed on ice for cooling. The vector linearization enzyme digestion reaction system: pECMV-MCS-FLAG vector 1 μg, restriction endonucleases EcoRI and KpnⅠ 1 μL each, 10×NEBuffer (rCutSmart) 5 μL, ddH 2 Make up to 50 μL with 5% HO, mix thoroughly by pipetting, and digest at 37°C for 1 h.

[0046] c. Thaw the competent cells on ice, take 10 μL of the recombinant product and add it to 100 μL of DH5α competent cells, gently pipette to mix, and place on ice for 30 minutes. After heat shock in a 42℃ metal bath for 45 seconds, immediately place on ice to cool for 2-3 minutes.

[0047] d. Add 900 μL of antibiotic-free LB medium and shake at 37°C for 1 hour (speed 250 rpm). Use a sterile spreader to spread evenly on an ampicillin-resistant LB agar plate (containing 50 μg / mL ampicillin) in a clean bench and invert and culture in a 37°C incubator for 14 hours.

[0048] e. Pick a single colony, add ampicillin-resistant LB liquid culture medium (containing 50 μg / mL ampicillin), shake briefly, and take 500 μL of the bacterial solution for sequencing and positive clone identification.

[0049] f. After the positive clones were expanded using LB liquid medium containing ampicillin, the recombinant plasmid was extracted using an endotoxin-free plasmid extraction kit and the NanoDrop TM After passing the quality inspection of One Micro-Spectrophotometer, store it at -80℃ until use.

[0050] (2) Interference vector construction

[0051] According to the porcine PPARD gene sequence in the NCBI database (Gene ID: NM_001130241.3), the BLOCK-iT TM RNAi Designer software was used to design three pairs of siRNA targeting the PPARD gene and one pair of negative control (si-NC). The siRNA was synthesized by Suzhou Genema Gene Co., Ltd. The sequence information is shown in Table 4.

[0052] Table 4 siRNA sequence information of PPARD gene

[0053]

[0054] (3) Transfection

[0055] IPEC-J2 cells were cultured at 1.5 × 10 5 The cells were inoculated into 6-well plates at a density of 100 μL / well and transfected when the density reached 70%. The transfection complex was prepared in a 1.5 mL sterile EP tube. The system was: 100 μL jetPRIMEBuffer per well, 2 μL siRNA / 2 μg plasmid, 4 μL jetPRIME Reagent universal in vitro transfection reagent, vortexed for 10 seconds, and incubated at room temperature for 10 minutes after instantaneous separation. After washing the cells with PBS, fresh culture medium was replaced, and the transfection complex was added to the corresponding wells. RNA was collected for 24 hours and protein was collected for 48 hours. Overexpression and interference efficiency were detected by qPCR and Western blot.

[0056] 2. Verification of overexpression efficiency

[0057] The present invention detects the overexpression efficiency by qPCR. The specific steps are as follows:

[0058] (1) Extraction of total cellular RNA

[0059] This study used the TRIzol method to extract total cell RNA. The specific steps are as follows:

[0060] a. After washing the transfected IPEC-J2 cells with PBS, add 1 mL of TRIzol to each well and collect the cells in a 1.5 mL EP tube after thorough pipetting.

[0061] b. Add 200 μL of chloroform to each tube, vortex for 30 seconds, and centrifuge at 12,800 rpm at 4°C for 15 minutes.

[0062] c. Pipette 400 μL of supernatant into a new 1.5 mL enzyme-free EP tube, add an equal volume of ice-cold isopropanol, mix by inversion, and centrifuge at 12,800 rpm at 4°C for 10 min.

[0063] d. Discard the supernatant and keep the precipitate. Add 1 mL of pre-cooled 75% ethanol, gently shake to elute the sample precipitate, and centrifuge at 12,800 rpm at 4°C for 10 min. Repeat twice to absorb as much residual ethanol as possible, open the lid and let it stand for 3 min to allow the ethanol to evaporate completely.

[0064] e. Add 30 μL RNase-free ddHO 2 O and vortex thoroughly to dissolve RNA. Centrifuge briefly and measure RNA quality.

[0065] f. Follow the instructions and use NanoDrop TM After passing the quality inspection of One Micro-Spectrophotometer, store it at -80℃ until use.

[0066] (2) cDNA synthesis

[0067] Using total cell RNA as a template, use a reverse transcription kit to convert cDNA. The steps are as follows:

[0068] a. Genomic DNA removal: According to the reaction system shown in Table 5, prepare the premix in an enzyme-free microcentrifuge tube, gently pipette to mix, and react in a 42°C metal bath for 2 min.

[0069] Table 5 gDNA removal reaction system

[0070]

[0071]

[0072] b. Reverse transcription reaction: Prepare the reaction mixture according to the system shown in Table 6, mix well by pipetting, and synthesize cDNA in a PCR instrument according to the program of 50℃15min, 85℃5s. After the reaction program is completed, store the cDNA sample at -20℃ for later use.

[0073] Table 6 Reverse transcription reaction system

[0074]

[0075] (3) qPCR detection

[0076] Using cDNA as a template, prepare the mixture according to the reaction system shown in Table 7, vortex mix it and add it to a fluorescent quantitative 96-well plate, and detect its CT value according to the reaction program shown in Table 8. GAPDH was used as the internal reference gene, and 2 -ΔΔCt The relative expression level of the target gene was analyzed by the primer information as shown in Table 9.

[0077] Table 7 qPCR reaction system

[0078]

[0079] Table 8 qPCR reaction program

[0080]

[0081] Table 9 qPCR primer information

[0082]

[0083] 3. Western blot detection of protein expression

[0084] (1) Total protein extraction and BCA concentration determination

[0085] After the IPEC-J2 cells treated in the "PPARD overexpression and interference vector construction" step were washed three times with PBS, RIPA lysis buffer was added to each well and lysed on ice for 30 minutes. After lysis, the lysate and cell pellet were transferred to a 1.5 mL centrifuge tube using a cell scraper and centrifuged at 14000 rpm for 20 minutes. The supernatant was transferred to a new centrifuge tube for use, and the protein concentration was determined using the BCA Protein Assay Kit.

[0086] (2) Protein quality homogenization and protein denaturation

[0087] After unifying the protein mass according to the protein concentration and volume, add 5×SDS-PAGE protein loading buffer and heat in a 98℃ metal bath for 10 min to denature the protein. The denatured protein sample is stored at -80℃ for later use.

[0088] (3) SDS-PAGE gel electrophoresis and membrane transfer

[0089] Prepare PAGE gel using a gel preparation kit, add the corresponding sample after the gel solidifies, and perform electrophoresis using Tris-Gly buffer. After 80V constant voltage electrophoresis for 30 minutes, electrophoresis at 120V until the indicator band runs out of the bottom of the gel and then stops.

[0090] (4) Immunoblotting-membrane transfer

[0091] Cut the PVDF membrane of appropriate size according to the gel size, activate it with methanol and transfer it, insert the transfer clip into the transfer rack and put it into the electrophoresis tank, add 500mL transfer buffer, cover the safety cover, turn on the power and start electrophoresis. The transfer condition is constant current 300A, 60min.

[0092] (5) Blocking and antibody incubation

[0093] After the transfer is completed, the PVDF membrane is blocked with 5% skim milk powder at room temperature for 2 hours, and then washed with TBST 3 times for antibody incubation. After cutting the PVDF membrane according to the size of the protein band, it is placed in the antibody incubation box, and 10mL of the corresponding primary antibody (PPARD, ZO-1, Claudin-1, Occludin or GAPDH) diluted at a ratio of 1:1000 is added and incubated overnight on a shaker at 4°C. After the primary antibody incubation is completed, the antibody is recovered, and after washing 3 times with TBST, 10mL of mouse and rabbit horseradish peroxidase-coupled secondary antibodies diluted at a ratio of 1:1000 are added, and the membrane is placed on a decolorizing shaker for incubation at room temperature for 2 hours, the antibody is recovered, and the membrane is washed 3 times with TBST for development.

[0094] (6) Development

[0095] After absorbing the TBST on the membrane with filter paper, it was placed in a developer solution and incubated in the dark for 2 minutes, and the image was collected using a Tianneng chemiluminescence imager.

[0096] 4. Cellular Reactive Oxygen Species Detection

[0097] IPEC-J2 cells were plated at 3 × 10 5The cells were inoculated in a 6-well plate at a density of 100 μM and cultured for 12 hours. After pretreatment with 2 μM curcumin (CUR) for 24 hours, 20 μM OTA was added and cultured for 48 hours. After washing the cells with PBS three times, the cells were digested with trypsin preheated at 37°C, centrifuged at 1000 rpm for 5 minutes, and the supernatant was discarded. 1 mL of DCFH-DA diluent (DCFH-DA: Opti-MEM medium = 1:1000, v / v) was added to the cell pellet to resuspend the cells, incubated at 37°C for 20 minutes, and inverted and mixed once every 3 minutes. After incubation, centrifuged at 1000 rpm for 5 minutes, discarded the supernatant, and the cell pellet was washed with PBS to wash away the unbound fluorescent probe. Finally, 300 μL PBS was added to resuspend the cell pellet, and the sample was detected by flow cytometry at an excitation wavelength of 488 nm and an emission wavelength of 525 nm, and the results were analyzed using CytExpert software.

[0098] Example 1: Overexpression of PPARD can reduce OTA-induced cellular oxidative stress and intestinal barrier damage

[0099] In this example, a PPARD overexpression vector (PPARD-OE) was constructed according to the above method, and IPEC-J2 cells were transfected with it. After 24 hours, 20 μM OTA was added for 48 hours, and the intracellular ROS level and the expression levels of tight junction proteins ZO-1, Occludin and Claudin-1 were detected. The results of qPCR quantitative detection showed that the PPARD mRNA level was significantly increased ( Figure 1 A), indicating that the overexpression vector has been successfully expressed in the cells. In addition, Western blot analysis found that PPARD overexpression significantly alleviated the inhibition of OTA on the expression of tight junction proteins ZO-1, Occludin and Cludin-1 ( Figure 1 B), and significantly reduced the increase in ROS levels induced by OTA ( Figure 1 C). The above results indicate that PPARD can alleviate OTA-induced intestinal barrier damage and oxidative stress, thereby reducing OTA-induced cytotoxicity.

[0100] Example 2: Curcumin promotes PPARD expression

[0101] In this example, a PPARD overexpression vector was constructed according to the above method, and the vector was transfected into IPEC-J2 cells. Different doses of curcumin (0, 1, 2 μM) were used to treat IPEC-J2 cells for 24 h, and the expression changes of PPARD were detected by qPCR and Western blot. It was found that curcumin could overexpress PPARD in mRNA ( Figure 2 A) and protein levels ( Figure 2 B) Significantly promoted the expression of PPARD, indicating that PPARD could serve as a molecular target of curcumin.

[0102] Example 3: PPARD as a molecular target of curcumin to reduce OTA-induced toxic effects

[0103] In this example, a PPARD overexpression vector was constructed according to the above method, and IPEC-J2 cells were transfected with it. IPEC-J2 cells were pretreated with curcumin for 24 hours, and then 20 μM OTA was added for 48 hours. The ROS levels in cells of different treatment groups were detected by flow cytometry. At the same time, the expression changes of tight junction proteins were detected by Western blot. The results showed that the addition of curcumin can significantly reduce the level of OTA-induced cell oxidative stress ( Figure 3 A and 3B). Western blot results showed that curcumin could significantly alleviate the OTA-induced inhibition of tight junction protein expression (ZO-1, Occludin and Cludin-1). Figure 3 C).

[0104] Furthermore, siRNA technology was used to interfere with the expression of PPARD in IPEC-J2 cells (IPEC-J2 cells were transfected with the siRNA sequences described in Table 2, and the experiment was performed according to the method of Example 3). Western blot and qPCR verification showed that the expression levels of PPARD mRNA and protein were significantly decreased, indicating that the expression of PPARD had been successfully interfered ( Figure 4 A). In IPEC-J2 cells with disturbed PPARD expression, 2 μM curcumin was added for pretreatment for 24 h, and then 20 μM OTA was added for treatment for 48 h. Western blot analysis showed that the disturbance of PPARD expression aggravated the OTA-induced inhibition of tight junction protein expression of ZO-1, Occludin and Claudin-1, and weakened the alleviating effect of curcumin on the inhibition of tight junction protein expression of ZO-1, Occludin and Claudin-1 induced by OTA ( Figure 4 B).

[0105] These results indicate that PPARD can serve as a molecular target of curcumin to alleviate OTA-induced oxidative stress and intestinal barrier damage, thereby reducing the toxic effects of mycotoxins.

Claims

1. Use of the PPARD gene with accession number NM_001130241.3 or its siRNA in the preparation of drugs for regulating the toxicity of mycotoxins.

2. Use of the PPARD gene or the protein encoded by it in the preparation of a drug for preventing and / or treating mycotoxin poisoning.

3. Use of the PPARD gene or the protein it encodes in the preparation of drugs for alleviating the toxicity of mycotoxins.

4. The use according to claim 2 or 3, characterized in that: It includes overexpressing the PPARD gene or activating the expression of the PPARD gene.

5. The application according to claim 4, characterized in that: The method for activating PPARD gene expression comprises using a PPARD activator.

6. The use according to claim 5, characterized in that: The PPARD activator includes curcumin.

7. Use of curcumin in the preparation of a medicament for preventing and / or treating mycotoxin poisoning.

8. A drug for preventing and / or treating mycotoxin poisoning or alleviating mycotoxin toxicity, characterized in that: The drug activates the expression of the PPARD gene or protein.

9. The drug according to claim 8, characterized in that: It also includes curcumin.

10. The use according to any one of claims 1 to 7 or the medicine according to claim 8 or 9, characterized in that: The dosage form of the drug includes oral solution, injection, tablet, pill, dispersant, capsule, dripping pill, granule, suspension or emulsion.

Citation Information

Patent Citations

  • Traditional Chinese medicine composition for treating / preventing mycotoxin poisoning as well as preparation method and application of traditional Chinese medicine composition

    CN115192683A

  • Aptamers for mycotoxin detoxification

    US20180325936A1

  • Uses of mycotoxin-detoxifying antibodies

    WO2017083964A1